



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 33/26	A1	(11) International Publication Number: WO 92/01458 (43) International Publication Date: 6 February 1992 (06.02.92)
(21) International Application Number: PCT/US90/04166 (22) International Filing Date: 25 July 1990 (25.07.90) (71) Applicant: PURDUE RESEARCH FOUNDATION [US/US]; Division of Sponsored Programs, 328 ENAD, West Lafayette, IN 47907 (US). (72) Inventors: HEM, Stanley, L. ; 111 Pathway Lane, West Lafayette, IN 47906 (US). WHITE, Joe, L. ; 2505 Roselawn Avenue, Lafayette, IN 47904 (US). (74) Agents: LAMMERT, Steven, R. et al.; Barnes & Thornburg, 11 South Meridian Street, 1313 Merchants Bank Building, Indianapolis, IN 46204 (US).		(81) Designated States: AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH (European patent), CM (OAPI patent), DE (European patent)*, DK (European patent), ES (European patent), FI, FR (European patent), GA (OAPI patent), GB (European patent), HU, IT (European patent), JP, KP, KR, LK, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL (European patent), NO, RO, SD, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent). Published <i>With international search report.</i>
(54) Title: METHOD AND COMPOSITION FOR TREATMENT OF HYPERPHOSPHATEMIA (57) Abstract Oxy-iron compounds are useful for the treatment and prevention of hyperphosphatemia. Such compounds, particularly those exhibiting high surface area, can be administered orally to bind and inhibit absorption of dietary phosphate, or such compounds can be contacted with the dialysate in a hemodialysis unit to enhance reduction of serum phosphate of patients undergoing hemodialysis.		

• DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

+ DESIGNATIONS OF "SU"

It is not yet known for which States of the former Soviet Union any designation of the Soviet Union has effect.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LJ	Liechtenstein	SU ⁺	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
DE [*]	Germany	MC	Monaco	US	United States of America
DK	Denmark				

-1-

**METHOD AND COMPOSITION FOR
TREATMENT OF HYPERPHOSPHATEMIA**

5

This invention relates to the control of serum phosphate. More particularly, this invention is directed to a method for treatment and prevention of hyperphosphatemia in patients suffering that condition or predisposed to development of that condition.

10

Hyperphosphatemia in patients with chronic renal failure is a serious problem which may lead to osteitis fibrosa or calcium phosphate deposition in soft tissue. Various approaches have been used to lower serum phosphate. Aluminum hydroxide in an oral dosage form has been used to bind dietary phosphate. However, aluminum accumulates in patients with renal failure and its accumulation has been associated with dysfunction of various organ systems. Aluminum-associated osteomalacia has been shown to occur in patients whose only substantial exposure to aluminum was their intake of aluminum-containing phosphate binders.

15

20

Calcium carbonate therapy is another method which has been used for serum phosphate control. Serum calcium levels are known to increase significantly after treatment with calcium carbonate, in spite of decreased mean calcitriol dosage and suppression of parathyroid activity. This increase in serum calcium is thought to be attributed to increased gastrointestinal absorption of calcium that is not vitamin D dependent.

25

30

Calcification of soft tissues and the vasculature are a potential risk associated with elevated calcium/phosphate ion product. Metastatic

-2-

5 calcifications of the eyes, joints, viscera, skin and
arteries can occur as calcium phosphate salts
precipitate as a direct consequence of supersaturation
of body fluids with calcium phosphates.
Hyperphosphatemia has been seen as the most important
factor in the mechanism of soft-tissue calcification in
uremia. Additionally, calcium carbonate is not suitable
10 for use in chronic renal failure patients who are
hypercalcemic. Gastrointestinal distress may be
manifested in some patients taking calcium carbonate. A
recent letter in the New England Journal of Medicine
[Stein et al., Vol. 316, p. 109 (1987)] reported high
15 serum values and pancolonic impaction in patients with
end-stage renal disease in which calcium carbonate was
substituted for aluminum binders. The writers there
cautioned against overzealous use of calcium carbonate
as a phosphate binder.

20 Magnesium-containing phosphate binders have
been used for treatment of hyperphosphatemia. However,
such binders have been associated with hypermagnesemia,
even with the use of a low magnesium dialysate. Other
products advocated for use as phosphate binders such as
25 calcium and iron cation loaded polyuronic acids require
dosages of 5-10 grams per day.

30 There is recognized in the medical community a
significant need for the development of a phosphate
binder which ideally should be palatable, free of even
minor side effects, inexpensive and very efficient in
binding phosphate under physiological conditions.
Accordingly, it is one object of this invention to

-3-

provide a method for controlling serum phosphate
utilizing a phosphate binding oxy-iron compound.

5

It is another object of this invention to
provide a composition in an oral dosage form for
inhibiting the absorption of dietary phosphate.

10

It is still another object of this invention to
provide a composition which not only has been identified
as an efficient phosphate binder, but has the added
advantage of being insoluble or but slightly soluble in
physiological fluids.

15

Another object of this invention is to provide
a method for enhancing reduction of a patient's serum
phosphate levels during hemodialysis by contacting a
phosphate binding oxy-iron compound with the dialysate.

20

In accordance with this invention oxy-iron
compounds, including particularly iron oxides and iron
oxyhydroxides, have been determined to be effective
agents for preventing absorption of ingested phosphates
in the digestive tract. Not only do such compositions
exhibit a high adsorptive capacity for phosphate, but
they also exhibit low solubility in physiological
fluids, including gastric juices, thereby lessening the
probability of side effects due to absorption of
solubilized iron compounds. Oxy-iron compounds can be
utilized in accordance with this invention in an oral
dosage form to bind and thereby prevent absorption of
ingested phosphate from the intestine and,

25

30

alternatively, can be used as an additive in dialysate
used for hemodialysis to effect and maintain a low
phosphate concentration in the dialysate and thereby

promote reduction of a patient's serum phosphate level during hemodialysis.

5

Synthetic ferrihydrite

($\text{Fe}_5\text{O}_7(\text{OH}) \cdot 4\text{H}_2\text{O}$), a preferred oxy-iron compound for use in accordance with the present invention has been found to exhibit a high adsorptive capacity for phosphate, 32 mg P/g and was virtually insoluble in
10 simulated gastric acid. It is projected that a 174 mg dose of ferrihydrite can adsorb the same amount of phosphate as 10 ml of the art-recognized aluminum hydroxide phosphate binder.

There is provided, in accordance with this
15 invention, a method of controlling serum phosphate levels in patients suffering from hyperphosphatemia or patients predisposed to development of a hyperphosphatemic condition. Patients experiencing chronic or acute renal insufficiencies requiring
20 dialysis are among those most prone to develop hyperphosphatemic conditions.

The method in accordance with this invention comprises contacting ingested phosphate with an oxy-iron compound selected from the group consisting of iron
25 oxides, iron oxyhydroxides, and iron hydroxides. Therapeutic benefit can be realized in accordance with such method by administering an oxyacid compound orally to a patient to contact and bind with ingested phosphate in the patient's digestive tract, and thereby prevent
30 its systemic absorption.

Alternatively, the oxy-iron compound can be utilized to contact phosphate in the dialysate of a

hemodialysis (artificial kidney) unit wherein substances are removed from the blood by diffusion across a semi-permeable membrane into a second fluid (the dialysate). Hemodialysis systems are well known in the art. See, for example, that described in U.S. Patent No. 4,581,141, issued April 8, 1986, the disclosure of which is incorporated herein by reference. The addition of an oxy-iron compound to the dialysate lowers the concentration of phosphate dissolved in the dialysate and thereby enhances the concentration differential dependent migration of phosphate ions from the patient's blood across the intermediate semi-permeable membrane and into the dialysate. Whether the oxy-iron compound is brought into contact with ingested phosphate in the digestive tract of a patient or in a dialysate utilized for patient hemodialysis, the phosphate binding oxy-iron compound is effective to control (i.e., prevent the build-up) of phosphate ions in the patient's body fluids, while at the same time, due to their low solubility, provide little risk of side effects.

Oxy-iron compounds useful in accordance with the present invention include iron oxides, iron hydroxides, and iron oxyhydroxides. Many such compounds are known in the art. Suitable oxy-iron compounds include naturally occurring and synthetic forms of the following minerals: Hematite (α -Fe₂O₃), Ilmenite (FeTiO₃), Magnetite (Fe₃O₄), Maghemite (γ -Fe₂O₃), Goethite (α -FeOOH), Lepidocrocite (γ -FeOOH), Akaganeite (β -FeOOH), Ferrihydrite (Fe₅O₇(OH)·4H₂O), and Ferroxihite (δ' -FeOOH).

Suitable oxy-iron compounds can be amorphous or crystalline and include, as well, iron oxides and iron oxyhydroxides that can be prepared by coprecipitation of iron with one or more other metal ions. It is preferred that oxy-iron compounds for use in accordance with the present invention have a surface area of at least 50 m²/g to about 500 m²/g, more preferably at least about 200 m²/g. Typically the higher the surface area, the more efficient the oxy-iron compound is as a phosphate binder. Preferred oxy-iron compounds for use in accordance with this invention, therefore, exhibit low solubility in gastric acids and physiological fluids, and high surface area/phosphate binding capacity. Synthetic ferrihydrite is most preferred because of its high surface area.

In a preferred embodiment of this invention, the oxy-iron compounds are formulated as a therapeutic dosage form for oral administration to a patient afflicted with hyperphosphatemia or predisposed to develop that condition. Thus, the oxy-iron compound can be formulated with suitable excipients as a liquid or gel suspension, or in a unitary solid dosage form such as a compressed tablet or capsule. Pharmaceutically acceptable methods and excipients for preparation of liquid, gel and solid dosage forms for oral administration are well known in the art. The oral dosage form should be formulated to contain sufficient oxy-iron compound to bind, upon ingestion by the patient, sufficient ingested phosphate in the patient's intestinal tract to inhibit the absorption of ingested

-7-

phosphate and thereby reduce the probability of either the development of a hyperphosphatemic condition or the complication of an already existing hyperphosphatemic condition. Thus, each oral dose of the therapeutic oxy-iron containing composition in accordance with this invention can contain from about 50 mg to about 500 mg or more of oxy-iron compound. The amount of oxy-iron compound to be administered will depend on the severity of the patient's condition, the nature of the patient's diet and the surface area/phosphate binding capacity of the oxy-iron compound used in the formulation. The dosages of oxy-iron compounds to be administered in accordance with this invention can be increased, if necessary, to correspond to the level of phosphate binding required in the patient's digestive tract.

In an alternative embodiment of this invention, an oxy-iron compound can be contacted with the dialysate of a hemodialysis unit (an artificial kidney) to reduce the concentration of soluble phosphate in the dialysate. Thus a dialysate having enhanced phosphate absorption can be prepared by combining an oxyiron compound with a sterile dialysis compatible carrier therefor. The carrier is preferably a combination of other functional dialysate components in a sterile aqueous slurry or solution or a pre-mix of such components for forming a dialysate slurry or solution. The reduced soluble phosphate concentration in the dialysate effected by the oxyiron component enhances diffusion of phosphate in the patient's blood across the semi-permeable membrane separating the blood and the

5 dialysate in the hemodialysis unit. Thus, oxy-iron
compounds added to or contacted with the dialysate
function to enhance the reduction of a patient's serum
phosphate levels during hemodialysis. The phosphate
binding oxy-iron compound can be added to the dialysate,
for example, to a dialysis slurry such as that described
in U.S. Patent 4,581,141, issued April 8, 1986, or the
10 dialysate can be contacted with the oxy-iron compound by
circulation through a separate cartridge or chamber
containing the oxy-iron compound in which soluble
phosphate in the dialysate is bound by the contained
oxy-iron compound.

15 Oxy-iron compounds utilized in accordance with
the present invention exhibit low water solubility over
a wide pH range. Thus, they contribute little to the
levels of soluble iron concentration in either the
digestive tract or in the dialysate of a hemodialysis
20 unit. This offers a significant advantage for the use
of the oxy-iron compounds in accordance with this
invention over the aluminum and calcium-containing
phosphate binders which have been used heretofore to
treat and prevent hyperphosphatemia.

25

EXAMPLES

Methods and Materials

30 Two iron oxide minerals, goethite and
ferrihydrite, were evaluated for potential phosphate
binding properties. These minerals occur naturally in
soils and can be easily synthesized. Goethite was
prepared by pouring 900 ml of 1 M KOH into 100 ml of 1 N

-9-

5 $\text{Fe}(\text{NO}_3)_3 \cdot 9 \text{H}_2\text{O}$ contained in a 2-liter propylene
bottle, then adding enough deionized water to make 2
liters of solution. The suspension was placed in a
forced-draft oven at 70°C for 14 days to crystallize
goethite. The suspension was then adjusted to pH 7
using 1N HCl and dialyzed against deionized water for 4
days.

10 Ferrihydrite was synthesized by titrating 100
ml of 1 N $\text{Fe}(\text{NO}_3)_3 \cdot 9 \text{H}_2\text{O}$ with 1 N KOH to a
stable pH of 8 and then dialyzing the precipitate
against deionized water for 4 days.

15 Total iron content was determined after
dissolving 30 mg samples in 20-40 ml of concentrated
HCl. Oxalate-soluble iron was determined by extracting
30 mg samples in 20 ml of pH 3 ammonium oxalate in the
dark for 2 hours. Iron in the extracts was determined
by atomic absorption spectroscopy; surface area was
20 determined by ethylene glycol monoethyl ether absorption.

Adorption studies were conducted at pH 7.5,
37°C using radiolabeled P-32 to determine the phosphate
binding capacity. For each phosphate binder, 5 test
solutions were prepared having a final volume of 55 ml
25 and containing either 500 mg goethite or 50 mg
ferrihydrite along with a blank solution containing no
phosphate binder. The phosphorus concentrations in the
test solutions were 0.03139, 0.1405, 0.2992, 0.5011, and
0.7677 mg P/ml. The phosphorus concentration of the
30 blank was 0.5011 mg P/ml. Each solution, including the
blank, also contained approximately 2.2 μCi P-32.
Following a 3-hour absorption period in a 37°C

-10-

5 shaker/water bath and centrifugation at 5400 rpm for 25
minutes, the activity of 1 ml of clear supernatant from
each sample and the blank was determined using a liquid
scintillation counter with external standardization.
The activity value of the blank was subtracted from the
activity of the test solution to correct for radioactive
decay and self-absorption. These values were then used
10 to calculate the adsorptive parameters of goethite and
ferrihydrite.

The fraction of the dose expected to be
converted to soluble iron species in the stomach was
determined by pH-stat titration at pH 2 and 3, at 37°C.
15 These pH conditions were chosen because the pH of the
gastric contents may range from about 1 to about 3.5.

Self supporting mounts for X-ray powder
diffraction (XRD) were prepared from samples that had
20 been gently ground in an agate mortar. The sample was
back-filled into an aluminum sample holder and gently
pressed against unglazed paper. Step-scanned XRD
patterns were obtained at 0.05° increments and 2 second
counting time per increment using CoK α radiation (35
25 kV and 25 mA) at a Phillips PW 3100 goniometer equipped
with a 1° divergence slit, a 0.2 mm receiving slit, and
a graphite monochromator.

Results and Discussion

30 The XRD pattern of the synthesized materials
confirms their identity as goethite and ferrihydrite.
All of the diffraction lines in the goethite pattern

could be attributed to goethite, indicating that no other crystalline phases were present. The diffraction lines were sharp and narrow indicating that the goethite is highly crystalline. The diffraction pattern of ferrihydrite, on the other hand, showed only 2 broad diffraction lines at 2.6 Angstroms and 1.5 Angstroms which are characteristic of 2-line ferrihydrite.

The ratio of oxalate soluble iron to total iron (Fe_o/Fe_t) gives additional information on the purity of the two phases. Well-crystallized iron oxide minerals such as goethite are relatively insoluble in oxalate and have Fe_o/Fe_t ratios less than 0.03, while poorly crystallized minerals such as ferrihydrite have Fe_o/Fe_t ratios which approach 1.0. The synthetic goethite had an Fe_o/Fe_t ratio of 0.01 indicating that it contained only goethite, while the synthetic ferrihydrite had an Fe_o/Fe_t ratio of 0.97, indicating that it was essentially pure ferrihydrite.

Surface area data supports both the XRD and oxalate ratio findings. Goethite had a surface area of $82 \pm 3 \text{ m}^2/\text{g}$. This relatively low value is characteristic of its crystalline nature, previously noted by XRD and oxalate ratio evaluations. Ferrihydrite had a surface area of $405 \pm 22 \text{ m}^2/\text{g}$, which is characteristic of a very poorly crystallized solid.

Langmuir adsorption isotherms were determined for goethite and ferrihydrite. The adsorptive capacities are 6.1 mgP/g for goethite and 53.9 mgP/g for ferrihydrite. The adsorptive co-efficients are 16.2

-12-

L/mol for goethite and 15.6 L/mol for ferrihydrite. The adsorptive co-efficients, which are a measure of the strength of binding forces for absorption, are similar. This indicates that the difference between the two compounds is most likely a reflection of the amount of surface available for binding and not a difference in mechanism or strength of binding. The difference in adsorptive capacities can be attributed to the difference in surface area. The higher surface area compound, ferrihydrite, binds more phosphate than goethite.

A study was conducted to compare the amount of phosphorus adsorbed by synthetic goethite and synthetic ferrihydrite at phosphate concentrations similar to that achieved in intestinal fluid following meal. The synthetic ferrihydrite has been found to adsorb 3-5 times more phosphorus per gram than aluminum hydroxide suspensions. One 10 ml dose of Amphogel™, containing 420 mg equivalent Al_2O_3 adsorbs 3.9 mg P. In comparison, 174 mg of synthetic ferrihydrite or 1.05 g of synthetic goethite also adsorbs 3.9 mg P when in equilibrium with a solution containing 0.11 mg P/ml. Thus, a tablet or capsule containing 174 mg synthetic ferrihydrite is predicted to adsorb the same amount of phosphate as 10 ml of Amphogel™, a product now commercially utilized as a phosphate binder to treat or prevent hyperphosphatemia.

Phosphate absorption occurs in the intestine. However, the minimum gastric residence time in an oral product is estimated to be 15 minutes. The acidity of

-13-

the gastric contents may vary from pH 1.0 to 3.5. Dissolution of the phosphate binder due to the low pH of the stomach may lead to systemic absorption. Systemic absorption from long term use of aluminum-containing phosphate binders has led to aluminum toxicity resulting in secondary illnesses such as osteomalacic dialysis osteodystrophy, and dialysis dementia. Thus, the rate of acid dissolution under simulated gastric conditions was determined by pH-titration at pH 2 and 3. Table 1 lists the percent dissolved for both aluminum hydroxide and iron oxide compounds during the exposure to simulated gastric conditions.

TABLE 1

Rate of acid dissolution under simulated gastric conditions.

<u>Adsorbent</u>	<u>Percent Dissolved</u>			
	<u>pH 2</u>		<u>pH 3</u>	
	<u>15 min</u>	<u>60 min</u>	<u>15 min</u>	<u>60 min</u>
Alternagel			22	100
Amphogel			68	100
Basaljel			74	100
Synthetic goethite	0.3	0.6	0.3	0.6
Synthetic ferrihydrite	1	6	0.3	4

Virtually no dissolution of synthetic goethite or synthetic ferrihydrite occurred, even at pH 2 for 60 minutes. In contrast, the aluminum hydroxide phosphate binders were completely dissolved when exposed to pH 3 for 60 minutes. Oxy-iron compounds, most preferably ferrihydrite and other oxy-iron compounds exhibiting

-14-

5 surface areas in excess of 200 m²/g, due to their high
phosphate adsorptive capacity and low solubility in
gastric fluids, are therapeutic agents of choice for the
treatment and prevention of hyperphosphatemia.

10

15

20

25

30

What is claimed:

1. Method of controlling serum phosphate level in patients suffering from hyperphosphatemia or patients predisposed to development of a hyperphosphatemic condition, which method comprises contacting ingested phosphate with a oxy-iron compound selected from the group consisting of iron oxides, iron oxyhydroxides and iron hydroxides, in an amount effective to bind sufficient ingested phosphate to prevent or alleviate a condition of hyperphosphatemia.

2. The method of claim 1 wherein the oxy-iron compound has a surface area of at least about 50 m²/g.

3. The method of claim 1 wherein the compound has a surface area of at least 200 m²/g.

4. The method of claim 1 wherein the oxy-iron compound is administered to the patient orally for contact with ingested phosphate in the digestive tract.

5. The method of claim 4 wherein the iron-oxy compound has a surface area of about 50 to about 500 m²/g.

6. The method of claim 5 wherein the oxy-iron compound is an iron oxide or iron oxyhydroxide.

7. The method of claim 6 wherein the oxy-iron compound is goethite.

8. The method of claim 6 wherein the oxy-iron compound is ferrihydrite.

9. The method of claim 1 wherein the oxy-iron compound is a component of a dialysate and is contacted with the phosphate during patient hemodialysis.

-16-

10. The method of claim 9 wherein the oxy-iron compound is an iron oxide or an iron oxyhydroxide.

11. The method of claim 10 wherein the oxy-iron compound has a surface area of about 50 to about 500 m²/g.

12. The method of claim 10 wherein the oxy-iron compound is goethite.

13. The method of claim 10 wherein the oxy-iron compound is ferrihydrite.

14. A therapeutic composition in oral dosage form for controlling serum phosphate in patients having need for reduced absorption of dietary phosphate, said composition comprising an oxy-iron compound selected from the group consisting of iron oxides, iron oxyhydroxides, and iron hydroxides, in an amount effective to inhibit the absorption of dietary phosphate and a pharmaceutically acceptable excipient for said oral dosage form.

15. The composition of claim 14 wherein the oxy-iron compound has a surface area of about 50 to about 500 m²/g.

16. The composition of claim 14 wherein the compound is goethite.

17. The composition of claim 14 wherein the iron compound is ferrihydrite.

18. A method for enhancing reduction of a patient's serum phosphate levels during hemodialysis of said patient using a dialysate, said method comprising the step of contacting the dialysate with an oxy-iron compound selected from the group consisting of iron hydroxides, iron oxyhydroxides and iron oxides in an

-17-

amount sufficient to reduce the concentration of phosphate in said dialysate.

19. The method of claim 18 wherein the oxy-iron compound has a surface area of about 50 to about 500 m²/g.

20. The method of claim 18 wherein the oxy-iron compound is ferrihydrite.

21. A dialysate for use in accordance with the method of claim 18, said dialysate comprising an oxyiron compound selected from the group consisting of iron hydroxides, iron oxyhydroxides and iron oxides and a sterile carrier therefor.

22. A method for manufacture of a dialysate adapted for enhanced phosphate adsorption, said method comprising the step of combining an oxyiron compound selected from the group consisting of iron hydroxides, iron oxyhydroxides and iron oxides with a sterile carrier therefor.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US90/04166

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) *

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC (5) : A61K 33/26

U.S. Cl : 424/646,647,648

II. FIELDS SEARCHED

Minimum Documentation Searched *

Classification System |

Classification Symbols

U.S. 424/646,647,648

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched *

APS & CAS HYPERPHOSPHATEMIA (IRON OR FERROUS FERRIC) AND (PHOSPH?)

III. DOCUMENTS CONSIDERED TO BE RELEVANT **

Category *	Citation of Document, 16 with indication, where appropriate, of the relevant passages 17	Relevant to Claim No. 18
Y	US,A 4,181,718 (MASON ET AL) 01 January 1980 See the entire document.	1-22
Y	US,A 4,474,853 (WATANABE) 02 October 1984 See the entire document.	1-22
A	US,A 4,581,141 (ASH) 08 April 1986 See the Abstract.	1-22
A	US,A 4,668,400 (VEECH) 26 May 1987 See the Abstract.	1-22
Y	N, CHEMICAL ABSTRACTS, Volume 108, Issue 24, Abstract 210,969X (MANN ET AL) J. Colloidal Interface Science Volume 122, Issue 2, pages 326-335 (1988).	1-22

* Special categories of cited documents: 12

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search *

19 OCTOBER 1990

Date of Mailing of this International Search Report *

04 MAR 1991

International Searching Authority *

ISA/US

Signature of Authorized Officer

GARY HOLLINDEN

NGUYEN NGOC HO

INTERNATIONAL DIVISION